Kanafani Zeina A, Corey G Ralph
Division of Infectious Diseases, American University of Beirut Medical Center, Cairo Street, PO Box 11-0236/11D, Riad El Solh 1107 2020, Beirut, Lebanon.
Future Microbiol. 2009 Feb;4(1):25-33. doi: 10.2217/17460913.4.1.25.
Infections caused by resistant Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) are now posing a major health risk for patients in hospital and community settings. There is a need to evaluate new antibiotics that would offer reliable clinical efficacy combined with a favorable safety profile for the treatment of such infections. Ceftaroline is a new member of the cephalosporin class of antibiotics with expanded activity against Gram-positive pathogens such as MRSA, vancomycin-intermediate S. aureus, vancomycin-resistant S. aureus and multidrug-resistant Streptococcus pneumoniae, while retaining good activity against common Gram-negative organisms. Phase II and III studies have shown ceftaroline to be an effective and well-tolerated treatment for complicated skin and skin-structure infections compared with standard therapy. Trials are ongoing in the treatment of community-acquired pneumonia.
由耐甲氧西林金黄色葡萄球菌（MRSA）等耐药革兰氏阳性病原体引起的感染，目前正给医院和社区环境中的患者带来重大健康风险。有必要评估新的抗生素，这些抗生素在治疗此类感染时应具备可靠的临床疗效以及良好的安全性。头孢洛林是头孢菌素类抗生素的新成员，对革兰氏阳性病原体如MRSA、万古霉素中介金黄色葡萄球菌、万古霉素耐药金黄色葡萄球菌和多重耐药肺炎链球菌具有扩大的活性，同时对常见革兰氏阴性菌保持良好活性。II期和III期研究表明，与标准疗法相比，头孢洛林是治疗复杂皮肤和皮肤结构感染的有效且耐受性良好的疗法。社区获得性肺炎的治疗试验正在进行中。
